Springvest-led Desentum funding round raises EUR 28 million

• Springvest announced Desentum raised an oversubscribed EUR 28 million equity financing round, one of Finland’s largest for an unlisted drug developer.
• Funding combined a EUR 18 million public offering via Springvest’s platform with EUR 10 million from professional venture investors.
• Desentum is a Finnish clinical-stage biotech developing allergy immunotherapies using genetically modified allergens.
• Proceeds target three lead programs in birch, peanut, and cat allergy; birch candidate is in Phase II.
• Springvest said it has financed Desentum’s growth with EUR 54 million in total, holding just over 7% before pending registrations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Springvest Oyj published the original content used to generate this news brief on October 12, 2026, and is solely responsible for the information contained therein.